The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Torii to Market 2 Anti-HIV Drugs Containing Tenofovir Alafenamide in Japan
March 3, 2015
- Switch OTC Drug Market Grows to 162 Billion Yen in 2014: Fuji Keizai
March 3, 2015
- Novartis Offers Apologies over Biz Suspension, Vows to Prevent Recurrence
March 2, 2015
- Jinarc Approved for Autosomal Dominant Polycystic Kidney Disease in Canada: Otsuka
March 2, 2015
- Eli Lilly Aims to Lead Japan Diabetes Market by 2020
March 2, 2015
- MTPC Eyes Total Sales of Over 100 Billion Yen for Remicade, Simponi
February 27, 2015
- Takeda Launches Takecab, to Copromote with Otsuka
February 27, 2015
- Medicago Signs Up with US Govt Agency for Development of Production Process for Ebola Antibodies
February 27, 2015
- Shionogi to Reorganize in April to Beat Biz Strategy Goals for FY2020
February 26, 2015
- Avigan Shows Promise in Treatment of Ebola in Clinical Trial
February 26, 2015
- NanoCarrier Concludes Joint Research Agreement with Chugai to Develop Next-Generation Anticancer Drugs
February 26, 2015
- Eisai to File Halaven for Soft Tissue Sarcomas; PIII Study Results Show Significant Prolongation of OS
February 26, 2015
- Takeda to Acquire Turkish Firm for Up to 14.5 Billion Yen, Earn 13 Branded Generics
February 25, 2015
- Daiichi Sankyo to Shake Up Japan Organization as Olmetec Patent Expiry Nears
February 25, 2015
- Japan’s 6th SGLT-2 Inhibitor Jardiance Hits Market
February 25, 2015
- US FDA Accepts NDA for Lonsurf: Taiho
February 24, 2015
- Takeda, Queen Mary University of London to Collaborate for Novel Drug Discovery in Gastroenterology Field
February 24, 2015
- MHLW OKs Additional Indications for E Keppra, Adempas
February 23, 2015
- Sun Pharma Wins Japan Approval for Cravit Generics, Competition with Daiichi Sankyo Might Arise
February 23, 2015
- J-Pharma Initiates PI Trial of LAT1 Inhibitor
February 23, 2015
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…